ENTA

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Enanta Pharmaceuticals (ENTA – Research Report) and Cellectis SA (CLLS – Research Report) with bullish sentiments. Enanta Pharmaceuticals (ENTA) In a report issued on June 22, Brian Skorney from Robert W. Baird maintained a Buy rating on Enanta Pharmaceuticals, with a price target of $90.00. The company's shares closed last Thursday at $45.67, close to its 52-week low of $37.59. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-enanta-pharmaceuticals-enta-cellectis-sa-clls?utm_source=advfn.com&utm_medium=referral